Novavax Inc (NVAX)
$15.09
0.15 (1.00%)
NVAX Stock Quote Delayed 30 Minutes
3 of the Best Biotech Stocks for 2022 to Buy Now
These three biotech stocks have performed amazingly well of late and are more than likely to perform even better next year.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
1.12B
PE Ratio
-4.72
EPS
-3.2
Volume (Avg. Vol.)
742,257
Day's Range
$14.65 - $15.17
52-Week Range
$3.53 - $23.86
Dividend & Yield
N/A (N/A)
NVAX Stock Predictions, Articles, and Novavax Inc News
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
The weekend break is over and that means it's time to get back to work with the biggest pre-market stock movers for Monday!
NVAX Stock Pops as the WHO Grants Novavax’s Vaccine Emergency Use. 8 Things to Know.
Today, the WHO approved emergency use listing for Novavax's vaccine, Covovax. NVAX stock is popping today as a result.
While Novavax Stock Remains Cursed, It Might Be Time to Buy
Novavax is waiting on good news from the World Health Organization. An EUA would push it above $200. Is it time to buy this cursed stock?
NVAX Stock Is on Watch Ahead of WHO Meeting. Here’s What to Know.
NVAX stock is up in the air today ahead of an important WHO meeting to discuss approval of Novavax's vaccine EUA. Here's what to know.
Bet on Novavax as Ambitious Battle Against Covid-19 Goes Global
The war against the omicron variant is heating up, and NVAX stock holders can remain confident in Novavax's thorough and aggressive strategy.
Vaccine Stocks: Why MRNA, BNTX, NVAX, PFE Stocks Are Stumbling Today
Dr. Fauci has implied that the omicron variant may not be as severe as feared. Vaccine stocks have taken a hit as a result.
Dear NVAX Stock Fans, Mark Your Calendars for a Key Catalyst on Dec. 16
Novavax may be on the verge of receiving EUA from the WHO, but NVAX stock isn't moving much so far. Regardless, investors should be on watch.
Novavax Is Set To Gain From The New Covid Variant
Novavax will file for EUA this month while the new Covid variant brings back focus on vaccine stocks. Buy NVAX stock at the current level.
Novavax Can Still Find Growth Opportunities Abroad
NVAX stock has been listless in 2021, which is frustrating investors. Yet, Novavax is making headway on the international regulatory front.
Novavax Is a Buy Based on Its Outlook, But Not for the Long Haul
As the Novavax vaccine becomes approved by more and more countries, NVAX stock will likely climb in the near-to-medium term.
NVAX Stock Is on Watch as Novavax Joins the Omicron Variant Battle
Shares of NVAX stock have risen by 8% in the past week after the company announced a vaccine in works that would target the omicron variant.
Novavax Stock Looks To Be In Recovery Mode
Novavax is finally healing after months of being beaten down. Is this the start of a big rally or a fragile recovery for NVAX stock?
NVAX Stock Alert: 2 Big Reasons Novavax Shares Are Climbing Today
Today, shares of NVAX stock are taking off following a couple of key regulatory updates from the company from two core markets.
Novavax Stock Is a Long-Term Investment in an Extended Pandemic
Novavax may soon get authorisation from several countries and this will take the revenue to record high. NVAX stock is a long term buy.
Novavax Stock Is on the Way with Ramp up in EUA Filings
NVAX has fallen sharply recently, but the time is ripe to buy this stock and take advantage of near-term catalysts like EUA filings.
Novavax Looks Like a Bargain with Its Low Forward Earnings Multiple
Novavax looks cheap at just 6 times forward earnings. NVAX stock is likely worth at least 85% more at $314 once it receives vaccine approval.
Ignore the Naysayers and Invest in Novavax Stock
NVAX stock boasts one of the strongest long-term cases in the biotech industry despite being criticized by the press.
Massive Jump Is a Great Selling Opportunity For Novavax Stock
Although NVAX stock has recently been bolstered by good news, it may not be enough to overcome vaccine disinformation.
